Optitrop-Lung05 is a hit, as promised, and then some.

Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.

First human data for BeOne’s BGB-B2033 lack the wow factor.

First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.

Parabilis’s zolucatetide bids to be third to a rather small market.

Strategist-Frontline is set to begin, as the company reports first-line velzatinib data at ASCO.

The company diverges from Summit and Bristol/BioNTech with a pivotal endometrial trial.

Relapsed biliary tract cancer, and ASCO, beckon.

The phase 2/3 Revival trial will test a ven/aza combo in first-line AML.